RTI Header Image
Dear Subscriber,

Many people become familiar with our work as either patients, loved ones, or as a physician colleague. However, you may not realize that in addition to treating patients today, we also partner with pharmaceutical companies to identify the best treatments for tomorrow. Our laboratory has the unique ability to use tumor samples to test drugs in development, rather than on patients themselves. This gives pharmaceutical companies the data they need to move their drugs forward onto the next phase of FDA approval.

I am energized by these partnerships and look forward to continuing these ventures. Working with drug developers is yet another way we can ensure the best outcomes for patients today and in the future.

We are also excited about our participation at the upcoming American Association of Cancer Research meeting this April in Orlando, Fla. I will present research findings from one of our most exciting areas of investigation (an area that has benefited from our work with pharmaceutical partners) - the study of signal transduction inhibitors. These drugs, known as targeted agents, disrupt intracellular signals associated with cancer cell survival, invasiveness and proliferation.

Targeted agents were studies in the laboratory on human tumor samples to examine how cancer cells use these pathways for survival. The drugs were tested alone and in various combinations. It's my hope that these studies will one day enable us to select patients for these drugs more effectively and avoid the "trial and error" methods commonly used today. Our ongoing work is to unravel the mysteries of cell signaling at the level of function, rather than at the level of genomic profiles used at other centers.

Functional analysis is the best way for you to select treatments today. Our research ensures access to the cutting edge treatments of tomorrow.


Dr. Nagourney Signature
Dr. Robert Nagourney
Rational Therapeutics

From Physician to Patient -
A New Point of View 

There are some things we can only experience for ourselves.

Dr. John Friedberg

Just three months after getting his assay results, Dr. Friedberg and his dog Buddy hit the slopes.

Very few who have not had cancer would believe how little is known about treatment and how ineffective most of it is. As this becomes evident, we are dying. It is too late for most.

In my case, my chest was ravaged by metastatic kidney cancer. My red blood cells were mysteriously gone, the chemotherapy I had taken for three months had done nothing. I was not expected to live.

Good fortune led me to Robert Nagourney, MD. Just in the nick of time I made a "pilgrimage" to his office in Long Beach, California. The test, or "functional profile" of my tumor, led to a recommendation for a combination of three conventional anti-cancer drugs. However, none are drugs of choice for kidney cancer; none of them would have been used as "standard" therapy.

Within two weeks, my chest x-ray was clearing and my blood count was improving. I was feeling better. As of this writing, five months after diagnosis and two months on the new treatment, my chest metastases are "melting away."

I have no assurance that the army of kidney cancer cells, won't come back tomorrow. I may be living on borrowed time. I am choosing to use it to tell my story. Even though I'm a physician, I suspect my encounter with cancer is not that different from the experience of others.

Except, perhaps, for the outcome.

John Friedberg, MD

Board Certified Neurologist

Read more about patients and families whose lives have been touched by Rational Therapeutics.
In This Issue
A New Point of View
Website Redesign
New Early Detection Tool
Great New Book


Find us on Facebook
Our New Website  
We are excited to announce the launch of our new and improved website.

Rational Therapeutics website

This new design presents the the scientific information our patients and colleagues expect and combines it with some of the inspirational patient stories we've compiled over the years. You can now also access Dr. Nagourney's blog directly from the site.

Please visit us at
www. rational-t.com 

and let us know what you think!  

Blood Test for Cancer  

In recent years, it has been recognized that cancer patients circulate a small number of tumor cells in their blood. Using microbead technology, these cells can be isolated from the blood stream and characterized. The original application was as a prognostic marker by which patients with breast, colorectal or prostate cancers with high levels of circulating tumor cells, fell in the "high-risk" groups. Today, these tests may be used for a broader number of people, offering a new opportunity for earlier diagnosis.

 

Get Dr. Nagourney's insights on how this new technology might impact everyone. 

 

Get Customized Cancer Treatment!  



Pick up your copy of the latest book by
Ralph W. Moss, PhD, Customized Cancer Treatment.  
If you've already read the book, please leave a comment on the Amazon.com page so others can share in your experience.

Our Blogs
Hope Practiced Here
Read patient stories and learn about the advances at Rational Therapeutics.

Dr. Nagourney's Blog
Written by Robert Nagourney, MD, this blog is for physicians and scientists.